Search results for "Original Research Articles"

showing 10 items of 21 documents

Effects of Nandrolone Stimulation on Testosterone Biosynthesis in Leydig Cells

2016

Anabolic androgenic steroids (AAS) are among the drugs most used by athletes for improving physical performance, as well as for aesthetic purposes. A number of papers have showed the side effects of AAS in different organs and tissues. For example, AAS are known to suppress gonadotropin‐releasing hormone, luteinizing hormone, and follicle‐stimulating hormone. This study investigates the effects of nandrolone on testosterone biosynthesis in Leydig cells using various methods, including mass spectrometry, western blotting, confocal microscopy and quantitative real‐time PCR. The results obtained show that testosterone levels increase at a 3.9 μM concentration of nandrolone and return to the ba…

0301 basic medicineEnzymologicMalePhysiologyClinical BiochemistryAndrogenAnabolic Agents; Androgens; Animals; Cell Line; Cell Survival; Dose-Response Relationship Drug; Gene Expression Regulation Enzymologic; Leydig Cells; Male; Nandrolone; Phosphoproteins; Rats; Steroid 17-alpha-Hydroxylase; Testosterone; Physiology; Clinical Biochemistry; Cell BiologyAnabolic AgentsOriginal Research ArticlesNandroloneTestosteroneOriginal Research ArticleTestosteroneAnabolic Agents; Androgens; Animals; Cell Line; Cell Survival; Dose-Response Relationship Drug; Gene Expression Regulation Enzymologic; Leydig Cells; Male; Nandrolone; Phosphoproteins; Rats; Steroid 17-alpha-Hydroxylase; Testosterone; Clinical Biochemistry; Cell Biology; Physiology; Medicine (all)Steroidogenic acute regulatory proteinMedicine (all)Leydig CellsSteroid 17-alpha-HydroxylaseCYP17A1PhosphoproteinAndrogensDrugLuteinizing hormonemedicine.drugAnabolic Agents; Androgens; Animals; Cell Line; Cell Survival; Dose-Response Relationship Drug; Gene Expression Regulation Enzymologic; Leydig Cells; Male; Nandrolone; Phosphoproteins; Rats; Steroid 17-alpha-Hydroxylase; TestosteroneLeydig Cellendocrine systemmedicine.medical_specialtyCell SurvivalBiologyGene Expression Regulation EnzymologicCell LineDose-Response Relationship03 medical and health sciencesDownregulation and upregulationIn vivoInternal medicinemedicineAnimalsDose-Response Relationship DrugAnimalCell BiologyPhosphoproteinsRats030104 developmental biologyEndocrinologyGene Expression RegulationNandroloneAnabolic AgentRatHormone
researchProduct

HSP60 activity on human bronchial epithelial cells

2017

HSP60 has been implicated in chronic inflammatory disease pathogenesis, including chronic obstructive pulmonary disease (COPD), but the mechanisms by which this chaperonin would act are poorly understood. A number of studies suggest a role for extracellular HSP60, since it can be secreted from cells and bind Toll-like receptors; however, the effects of this stimulation have never been extensively studied. We investigated the effects (pro- or anti-inflammatory) of HSP60 in human bronchial epithelial cells (16-HBE) alone and in comparison with oxidative, inflammatory, or bacterial challenges. 16-HBE cells were cultured for 1–4 h in the absence or presence of HSP60, H2O2, lipopolysaccharide (…

0301 basic medicinep38αSettore BIO/17 - IstologiaLipopolysaccharidep38 mitogen-activated protein kinasesImmunologyStimulationBronchip38 Mitogen-Activated Protein KinasesERK1Cell LinePathogenesisMitochondrial Proteins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOriginal Research ArticlesHumansImmunology and AllergyCOPDInterleukin 8Protein kinase AReceptor16-HBE; COPD; CREB1; ERK1; HSP60; IL-10; IL-8; JNK1; MyD88; NF-κB p65 subunit; TLR-4; p38αPharmacologyIL-8Settore BIO/16 - Anatomia UmanaInterleukin-8JNK1NF-κB p65 subunitEpithelial CellsTLR-4Chaperonin 60MyD88Interleukin-1016-HBEToll-Like Receptor 416-HBE; COPD; CREB1; ERK1; HSP60; IL-10; IL-8; JNK1; MyD88; NF-κB p65 subunit; p38α; TLR-4; Immunology and Allergy; Immunology; PharmacologyInterleukin 10030104 developmental biologychemistry030220 oncology & carcinogenesisIL-10Cancer researchCREB1NF-κB p65 subunitHSP60p38α
researchProduct

International BEAT-PCD Consensus Statement for Infection Prevention and Control for Primary Ciliary Dyskinesia in collaboration with ERN-LUNG PCD Cor…

2021

Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative has now been taken towards creating such a consensus statement. Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP&C) for PCD, covering …

:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]Infeccions respiratòries en els infantsPrimary Ciliary DyskinesiaStatement (logic)Respiratory SystemMULTICENTERRECOMMENDATIONS0302 clinical medicineOriginal Research ArticlesPandemicSTENOTROPHOMONAS-MALTOPHILIAInfection control:Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [DISEASES]030212 general & internal medicinePrimary ciliary dyskinesiaMalalties transmissibles - Transmissió:Environmental Health::Health::Environmental Illness::Communicable Diseases::Communicable Disease Control [PUBLIC HEALTH]FOUNDATIONbiologyTransmission (medicine)R:Congenital Hereditary and Neonatal Diseases and Abnormalities::Congenital Abnormalities::Abnormalities Multiple::Ciliopathies::Congenital Hereditary and Neonatal Diseases and Abnormalities::Ciliary Motility Disorders [DISEASES]:afecciones patológicas signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedad crónica [ENFERMEDADES]:salud ambiental::salud::enfermedad ambiental::enfermedades transmisibles::control de enfermedades transmisibles [SALUD PÚBLICA]medicine.anatomical_structureMedicinePatient representativesLife Sciences & BiomedicinePulmonary and Respiratory Medicinemedicine.medical_specialty3610 Medicine & health:enfermedades y anomalías neonatales congénitas y hereditarias::anomalías congénitas::anomalías múltiples::ciliopatías::enfermedades y anomalías neonatales congénitas y hereditarias::trastornos de la motilidad ciliar [ENFERMEDADES]:Other subheadings::Other subheadings::/prevention & control [Other subheadings]03 medical and health sciencesotorhinolaryngologic diseasesmedicineIntensive care medicineScience & TechnologyCYSTIC-FIBROSISLungbusiness.industryPSEUDOMONAS-AERUGINOSAMalalties cròniques - PrevencióCAREEFFICACYmedicine.diseasebiology.organism_classificationrespiratory tract diseases030228 respiratory systemNontuberculous mycobacteria610 Medizin und GesundheitbusinessERJ Open Research
researchProduct

High Plasma Glutamate and a Low Glutamine-to-Glutamate Ratio Are Associated with Increased Risk of Heart Failure but Not Atrial Fibrillation in the P…

2020

[Background] Although the association between glutamate and glutamine in relation to cardiometabolic disorders has been evaluated, the role of these metabolites in the development of atrial fibrillation (AF) and heart failure (HF) remains unknown.

Blood GlucoseMalePREDIMEDmedicine.medical_specialtyGlutaminePopulationGlutamic AcidMedicine (miscellaneous)Heart failureDiet MediterraneanBody Mass IndexRisk FactorsOriginal Research ArticlesInternal medicinemedicineHumanseducationAgededucation.field_of_studyNutrition and Dieteticsbusiness.industryIncidence (epidemiology)Glutamate receptorAtrial fibrillationMiddle Agedmedicine.diseaseLipidsPredimedAtrial fibrillationGlutamineEndocrinologyQuartileCase-Control StudiesHeart failureFemaleGlutamatebusiness
researchProduct

Predictive value of heart failure with reduced versus preserved ejection fraction for outcome in pulmonary embolism

2020

Abstract Aims This study aimed to investigate whether the risk of short‐term mortality is different in pulmonary embolism (PE) patients who have heart failure with reduced ejection fraction (HFrEF) as compared with those with heart failure with preserved ejection fraction (HFpEF). Methods and results Predictive value of HFrEF or HFpEF for 7‐day (intrahospital) and 30‐day all‐cause mortality was determined in the cohort of 1055 out of 1201 consecutive acute PE patients from the Serbian multicentre PE registry. Patients were classified into either HFrEF or HFpEF group, according to guideline‐proposed criteria. A 7‐day (intrahospital) and 30‐day all‐cause mortality was 18.5% vs. 7.3% vs. 4.5% …

Ejection fractionmedicine.medical_specialtyHeart failure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineOriginal Research ArticlesInternal medicineDiseases of the circulatory (Cardiovascular) systemMedicineOriginal Research Article030212 general & internal medicineMortalityRisk factorEjection fractionbusiness.industryPulmonary embolismHazard ratioAtrial fibrillationmedicine.disease3. Good healthPulmonary embolismBlood pressureRC666-701Heart failureCardiologyCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionESC Heart Failure
researchProduct

Spirometric phenotypes from early childhood to young adulthood: a Chronic Airway Disease Early Stratification study

2021

Background The prevalences of obstructive and restrictive spirometric phenotypes, and their relation to early-life risk factors from childhood to young adulthood remain poorly understood. The aim was to explore these phenotypes and associations with well-known respiratory risk factors across ages and populations in European cohorts. Methods We studied 49 334 participants from 14 population-based cohorts in different age groups (≤10, >10–15, >15–20, >20–25 years, and overall, 5–25 years). The obstructive phenotype was defined as forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) z-score less than the lower limit of normal (LLN), whereas the restrictive phenotype was defined a…

Folkhälsovetenskap global hälsa socialmedicin och epidemiologiLung FunctionRespiratory Medicine and AllergyOriginal Research ArticlesRwf_140MedicinePublic Health Global Health Social Medicine and Epidemiology109wf_600Lungmedicin och allergiwf_20
researchProduct

Validity of the Seattle Heart Failure Model after heart failure hospitalization.

2019

Abstract Aims Heart failure hospitalization is a sentinel event associated with increased mortality risk. Whether long‐term heart failure risk models such as the Seattle Heart Failure Model (SHFM) accurately assess risk in the post‐hospital setting is unknown. Methods and results The SHFM was applied to a cohort of 2242 consecutive patients (50% women; mean age 73) on discharge after acute heart failure hospitalization and analysed for the primary endpoint of all‐cause mortality. Model discrimination and calibration were assessed. Direct patient‐level comparison between our study cohort and the original SHFM cohorts was also performed to confirm and quantify the degree and extent of increas…

Malemedicine.medical_specialty030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsSeattle Heart Failure ModelInternal medicineOriginal Research ArticlesClinical endpointmedicineHumansIn patient030212 general & internal medicineOriginal Research ArticleHospital dischargeMortality riskAgedAged 80 and overHeart FailureModels StatisticalReceiver operating characteristicbusiness.industryReproducibility of ResultsAcute heart failureMean ageAfter dischargeMiddle Agedmedicine.diseaseHospitalizationHeart failureAmbulatoryCohortCardiologyFemaleCardiology and Cardiovascular MedicinebusinessESC heart failure
researchProduct

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension.

2019

Purpose: To evaluate the additive intraocular pressure–lowering effect of twice-daily brinzolamide 1%/brimonidine 0.2% fixed-dose combination (BBFC) as an adjunct to a prostaglandin analog (PGA) in patients with open-angle glaucoma or ocular hypertension insufficiently controlled with PGA monotherapy. Methods: In this Phase 4, double-masked trial, patients aged ⩾18 years, with a mean intraocular pressure of ⩾19 and <32 mm Hg in at least one eye were randomized (1:1) to receive BBFC + PGA ( n = 96) or vehicle + PGA ( n = 92) for 6 weeks. The primary endpoint was the mean change in diurnal intraocular pressure from baseline (averaged over 09:00 and 11:00 h) at Week 6. Results: The mean diu…

Malemedicine.medical_specialtyOpen angle glaucomagenetic structuresFixed-dose combinationBrinzolamideThiazinesOcular hypertensionopen-angle glaucoma03 medical and health sciencesTonometry Ocular0302 clinical medicineTravoprostDouble-Blind Methodintraocular pressure reductionOphthalmologyOriginal Research ArticlesmedicineAdrenergic alpha-2 Receptor AgonistsHumansCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureAgedAged 80 and overSulfonamidesbusiness.industryprostaglandin analogsBrimonidineBrinzolamide/brimonidine fixed-dose combinationGeneral MedicineMiddle Agedmedicine.diseaseAdjuncteye diseasesOphthalmologyDrug CombinationsProstaglandin analogBrimonidine Tartrate030221 ophthalmology & optometryLatanoprostocular hypertensionFemalesense organsbusiness030217 neurology & neurosurgeryGlaucoma Open-Anglemedicine.drugEuropean journal of ophthalmology
researchProduct

Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study

2020

Altres ajuts: Conselleria d'Educació, Investigació, Cultura i Esport GV/2018/116 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low-density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle remodelling and heart failure-related complications. The aim of this study was to assess the relationship between circulating PCSK9 and 6 month cardiac magnetic resonance imaging-derived left ventricular ejection fraction (LVEF) after a first ST-segment elevation myocardial infarction (STEMI). We prospectively evaluated 40…

Malemedicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemLeft ventricular ejection fractionCardiac magnetic resonancemedicine.medical_treatmentMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme InhibitorsPilot Projects030204 cardiovascular system & hematologyVentricular Function LeftPCSK9Angiotensin Receptor Antagonists03 medical and health sciences0302 clinical medicineCardiac magnetic resonance imagingOriginal Research ArticlesInternal medicinemedicineST‐segment elevation myocardial infarctionHumansST segmentOriginal Research Article030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedKillip classEjection fractionmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionStroke VolumeMiddle Agedmedicine.diseaseST-segment elevation myocardial infarctionlcsh:RC666-701Heart failureCardiologyST Elevation Myocardial InfarctionProprotein Convertase 9Cardiology and Cardiovascular Medicinebusiness
researchProduct

Wake-up stroke and unknown-onset stroke; occurrence and characteristics from the nationwide Norwegian Stroke Register

2022

Introduction: Population-based knowledge of the characteristics of wake-up stroke and unknown-onset stroke is limited. We compared occurrence and characteristics of ischaemic and haemorrhagic wake-up stroke, unknown-onset stroke and known-onset stroke in a nationwide register-based study. Patients and methods: We included patients registered in the Norwegian Stroke Register from 2012 through 2019. Age, sex, risk factors, clinical characteristics, acute stroke treatment and discharge destination were compared according to stroke type and time of onset. Results: Of the 60,320 patients included, 11,451 (19%) had wake-up stroke, 11,098 (18.4%) had unknown time of onset and 37,771 (62.6%) had kn…

Original Research Articlescardiovascular diseasesNeurology (clinical)Cardiology and Cardiovascular MedicineVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752
researchProduct